RhumbLine Advisers
RBOT

RhumbLine Advisers’s Vicarious Surgical RBOT Stock Holding History

RhumbLine Advisers’s Portfolio RBOT Stock Details RBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-700
Closed -$4.11K – 4308
2024
Q2 		$4.11K Sell
700
-2,401
-77% -$21.5K ﹤0.01% 4114
2024
Q1 		$28K Buy
3,101
+17
+0.6% +$203 ﹤0.01% 3725
2023
Q4 		$33.9K Buy
3,084
+118
+4% +$1.31K ﹤0.01% 3698
2023
Q3 		$52.6K Buy
2,966
+195
+7% +$7.1K ﹤0.01% 3634
2023
Q2 		$152K Buy
2,771
+447
+19% +$28.5K ﹤0.01% 3374
2023
Q1 		$158K Buy
2,324
+68
+3% +$5.29K ﹤0.01% 2789
2022
Q4 		$137K Buy
2,256
+46
+2% +$4.28K ﹤0.01% 2863
2022
Q3 		$222K Buy
2,210
+149
+7% +$17.4K ﹤0.01% 2853
2022
Q2 		$182K Buy
+2,061
New +$252K ﹤0.01% 2954

Other funds holding RBOT

VS
VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return
DP
DDD Partners Bellevue, Washington $1.45B AUM 9.14% 1-Year Est. Return
MAMHA
MY.Alpha Management HK Advisors Hong Kong $246M AUM 73.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AMH
Aspex Management (HK) Central, Hong Kong $6.9B AUM 28.37% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return

RhumbLine Advisers's RBOT Position: Q3 2024 in Review

RhumbLine Advisers sold out of Vicarious Surgical (RBOT) in Q3 2024, closing a stake of 700 shares — an estimated $4.11K sold.

RhumbLine Advisers first reported a position in RBOT in Q2 2022 and held it in 9 quarters. The position peaked at $222K in Q3 2022. 34 funds tracked by Wall St. Rank hold RBOT as of Q3 2024.

  • RhumbLine Advisers reported no remaining Vicarious Surgical position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 700 Vicarious Surgical shares in Q3 2024, an estimated $4.11K.
  • RhumbLine Advisers first reported a position in Vicarious Surgical in Q2 2022 and held it in 9 quarters.
  • RhumbLine Advisers's Vicarious Surgical position peaked at $222K in Q3 2022.
  • 34 funds tracked by Wall St. Rank held Vicarious Surgical as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.